HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves New Indication for Sugemalimab

Stock News11-26

CSTONE PHARMA-B (02616) surged more than 5%, reaching HK$5.94 by the time of writing, with a trading volume of HK$8.23 million. The uptick follows the announcement on November 25 that the European Commission (EC) has approved a new indication for Sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).

Dr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, noted that this approval comes just one year after the EC first greenlit Sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024. The latest approval marks Sugemalimab's expanded coverage in Europe, spanning Stage III to IV NSCLC, offering a new therapeutic option for a broader patient population.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187055363?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187055363","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves New Indication for Sugemalimab","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) surged more than 5%, reaching HK$5.94 by the time of writing, with a trading volume of HK$8.23 million. The uptick follows the announcement on November 25 that the European Commission (EC) has approved a new indication for Sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).</p>\n<p>Dr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, noted that this approval comes just one year after the EC first greenlit Sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024. The latest approval marks Sugemalimab's expanded coverage in Europe, spanning Stage III to IV NSCLC, offering a new therapeutic option for a broader patient population.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves New Indication for Sugemalimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves New Indication for Sugemalimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-26 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) surged more than 5%, reaching HK$5.94 by the time of writing, with a trading volume of HK$8.23 million. The uptick follows the announcement on November 25 that the European Commission (EC) has approved a new indication for Sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).</p>\n<p>Dr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, noted that this approval comes just one year after the EC first greenlit Sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024. The latest approval marks Sugemalimab's expanded coverage in Europe, spanning Stage III to IV NSCLC, offering a new therapeutic option for a broader patient population.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1187055363","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187055363","pubTimestamp":1764122533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) surged more than 5%, reaching HK$5.94 by the time of writing, with a trading volume of HK$8.23 million. The uptick follows the announcement on November 25 that the European...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02616":"基石药业-B"},"translate_title":"港股动向|基石药业-B(02616)涨超5%因欧盟批准舒格利单抗新适应症","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CSTONE PHARMA-B (02616) surged more than 5%, reaching HK$5.94 by the time of writing, with a trading volume of HK$8.23 million. The uptick follows the announcement on November 25 that the European Commission (EC) has approved a new indication for Sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).\nDr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, noted that this approval comes just one year after the EC first greenlit Sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024. The latest approval marks Sugemalimab's expanded coverage in Europe, spanning Stage III to IV NSCLC, offering a new therapeutic option for a broader patient population.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187055363","isCrawlerRequest":true}